Innovative Pharmaceutical Biotech
Innovative Pharmaceutical Biotech, often referred to as IPB, is a leading player in the biotechnology sector, headquartered in Hong Kong. Founded in 2010, the company has rapidly established itself as a pioneer in the development of cutting-edge therapeutics and innovative drug delivery systems, primarily focusing on oncology and rare diseases. With a strong operational presence across Asia and Europe, IPB is renowned for its unique approach to biopharmaceuticals, leveraging advanced technologies to enhance treatment efficacy and patient outcomes. The company’s flagship products, which include targeted therapies and biologics, are distinguished by their precision and adaptability, setting new standards in the industry. Recognised for its commitment to research and development, Innovative Pharmaceutical Biotech has achieved significant milestones, positioning itself as a trusted name in the global biotech landscape.
DitchCarbon Score
How does Innovative Pharmaceutical Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Other Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Innovative Pharmaceutical Biotech's score of 5 is higher than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Innovative Pharmaceutical Biotech's reported carbon emissions
In 2023, Innovative Pharmaceutical Biotech reported total carbon emissions of approximately 9,640 kg CO2e, all of which were classified under Scope 2, specifically from purchased electricity. This marked a reduction from 11,260 kg CO2e in 2022 and 17,000 kg CO2e in 2021, indicating a significant downward trend in their emissions over the past two years. The company has not set specific reduction targets or climate pledges, which suggests a need for further commitment to formal climate initiatives. However, their emissions intensity per employee has shown improvement, decreasing from 450 kg CO2e in 2022 to 440 kg CO2e in 2023. Overall, while Innovative Pharmaceutical Biotech has made strides in reducing its carbon footprint, the absence of formal reduction targets highlights an opportunity for enhanced climate action and accountability in the future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | - | - | - |
| Scope 2 | 17,000 | 00,000 | 0,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Innovative Pharmaceutical Biotech is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
